litlas
ログインアカウント作成

R. Scott Obach

1996–2025 年に発表

121
論文数
21,656
被引用数
83
h 指数
119
i10 指数

被引用数

R. Scott Obach の年別被引用数1989 年: 被引用 1 件1995 年: 被引用 6 件1997 年: 被引用 2 件1998 年: 被引用 2 件1999 年: 被引用 6 件2000 年: 被引用 19 件2001 年: 被引用 39 件2002 年: 被引用 61 件2003 年: 被引用 54 件2004 年: 被引用 105 件2005 年: 被引用 144 件2006 年: 被引用 179 件2007 年: 被引用 213 件2008 年: 被引用 183 件2009 年: 被引用 233 件2010 年: 被引用 246 件2011 年: 被引用 264 件2012 年: 被引用 311 件2013 年: 被引用 226 件2014 年: 被引用 210 件2015 年: 被引用 184 件2016 年: 被引用 212 件2017 年: 被引用 162 件2018 年: 被引用 154 件2019 年: 被引用 500 件2020 年: 被引用 566 件2021 年: 被引用 519 件2022 年: 被引用 727 件2023 年: 被引用 522 件2024 年: 被引用 720 件2025 年: 被引用 292 件2026 年: 被引用 13 件1990〜1994 年は被引用が無いため表示していません1996 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,118 件、この内訳の 29.9%中国: 引用元論文 622 件、この内訳の 8.8%イギリス: 引用元論文 618 件、この内訳の 8.7%ドイツ: 引用元論文 395 件、この内訳の 5.6%スイス: 引用元論文 256 件、この内訳の 3.6%日本: 引用元論文 256 件、この内訳の 3.6%イタリア: 引用元論文 217 件、この内訳の 3.1%カナダ: 引用元論文 188 件、この内訳の 2.7%フランス: 引用元論文 179 件、この内訳の 2.5%スウェーデン: 引用元論文 173 件、この内訳の 2.4%オーストラリア: 引用元論文 152 件、この内訳の 2.1%インド: 引用元論文 144 件、この内訳の 2%
0%29.9%その他 25%

機関

分野

  • Medicine32.4%
  • Pharmacology, Toxicology and Pharmaceutics24.8%
  • Computer Science17.1%
  • Biochemistry, Genetics and Molecular Biology12.1%
  • Chemistry5.7%
  • Engineering1.8%
  • その他6.1%

トピック

  • Computational Drug Discovery Methods11.6%
  • Pharmacogenetics and Drug Metabolism11.3%
  • Drug Transport and Resistance Mechanisms5.1%
  • SARS-CoV-2 and COVID-19 Research4.3%
  • Analytical Chemistry and Chromatography2.5%
  • Drug-Induced Hepatotoxicity and Protection2.1%
  • その他63.1%

共著者

全論文

検索で開く
  1. An Oral SARS-CoV-2 M pro Inhibitor Clinical Candidate for the Treatment of COVID-19

    著者: Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson, Lisa Aschenbrenner, Melissa Avery, Simon Berritt, Britton Boras, Rhonda D. Cardin, Anthony Carlo, Karen J. Coffman, Alyssa Dantonio, Li Di, Heather Eng, Rose Ann Ferre, K.S. Gajiwala, Scott Gibson, S.E. Greasley, Brett L. Hurst, Eugene P. Kadar, Amit S. Kalgutkar, Jack C. Lee, Jisun Lee, Wei Liu, Stephen W. Mason, Stephen Noell, Jonathan J. Novak, R. Scott Obach, Kevin Ogilvie, Nandini C. Patel, Martin Pettersson, Devendra K. Rai, Matthew R. Reese, M. F. Sammons, Jean G. Sathish, Ravi Shankar Prasad Singh, Claire M. Steppan, Al Stewart, Jamison B. Tuttle, Lawrence W. Updyke, Patrick R. Verhoest, Liuqing Wei, Qingyi Yang, Yuao Zhu - Science 2021 被引用: 1,969

  2. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

    著者: Britton Boras, Rhys Jones, Brandon J. Anson, Dan Arenson, Lisa Aschenbrenner, Malina A. Bakowski, Nathan Beutler, Joseph Binder, Emily Chen, Heather Eng, Holly Hammond, Jennifer Hammond, Robert Haupt, Robert L. Hoffman, Eugene P. Kadar, Rob Kania, Emi Kimoto, Melanie G. Kirkpatrick, Lorraine F. Lanyon, Emma K. Lendy, Jonathan R. Lillis, James Logue, Suman Luthra, Chunlong Ma, Stephen W. Mason, Marisa E. McGrath, Stephen Noell, R. Scott Obach, Matthew N. O’ Brien, Rebecca E. O’Connor, Kevin Ogilvie, Dafydd R. Owen, Martin Pettersson, Matthew R. Reese, Thomas F. Rogers, Romel Rosales, Michelle I. Rossulek, Jean G. Sathish, Norimitsu Shirai, Claire M. Steppan, Martyn D. Ticehurst, Lawrence W. Updyke, Stuart Weston, Yuao Zhu, Kris M. White, Adolfo García‐Sastre, Jun Wang, Arnab K. Chatterjee, Andrew D. Mesecar, Matthew B. Frieman, Annaliesa S. Anderson, Charlotte Allerton - Nature Communications 2021 被引用: 296

  3. Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors

    著者: Mark E. Flanagan, J. A. Abramite, Dennis P. Anderson, Ann Aulabaugh, Upendra P. Dahal, A. Gilbert, Chao Li, Justin I. Montgomery, Stacey R. Oppenheimer, Tim F. Ryder, Brandon P. Schuff, Daniel P. Uccello, Gregory S. Walker, Yan Wu, Matthew F. Brown, Jinshan M. Chen, Matthew M. Hayward, Mark C. Noe, R. Scott Obach, Laurence Philippe, Veerabahu Shanmugasundaram, Michael J. Shapiro, Jeremy T. Starr, Justin G. Stroh, Ye Che - Journal of Medicinal Chemistry 2014 被引用: 324

  4. Managing the challenge of chemically reactive metabolites in drug development

    著者: B. Kevin Park, Alan R. Boobis, Stephen E. Clarke, Christopher E. Goldring, David Jones, J. Gerry Kenna, Craig Lambert, Hugh Laverty, Dean J. Naisbitt, Sidney D. Nelson, Deborah A. Nicoll‐Griffith, R. Scott Obach, Philip A. Routledge, Dennis A. Smith, Donald Tweedie, Nico Vermeulen, Dominic P. Williams, Ian D. Wilson, Thomas A. Baillie - Nature Reviews Drug Discovery 2011 被引用: 455

  5. Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds

    著者: R. Scott Obach, Franco Lombardo, Nigel J. Waters - Drug Metabolism and Disposition 2008 被引用: 454

  6. Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds

    著者: Franco Lombardo, Giuliano Berellini, R. Scott Obach - Drug Metabolism and Disposition 2018 被引用: 175

  7. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

    著者: R. Scott Obach, James G. Baxter, Theodore E. Liston, B. Michael Silber, Barry Jones, Fiona Macintyre, David J. Rance, Philip Wastall - Journal of Pharmacology and Experimental Therapeutics 1997 被引用: 638

  8. Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes

    著者: R. Scott Obach - Drug Metabolism and Disposition 1999 被引用: 1,219

  9. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19

    著者: Charlotte Allerton, Joel T. Arcari, Lisa Aschenbrenner, Melissa Avery, Bruce M. Bechle, Mohammad Amin Behzadi, Britton Boras, Leanne M. Buzon, Rhonda D. Cardin, Natasha R. Catlin, Anthony Carlo, Karen J. Coffman, Alyssa Dantonio, Li Di, Heather Eng, Kathleen A. Farley, Rose Ann Ferre, Steven Gernhardt, Scott Gibson, S.E. Greasley, Siennah R. Greenfield, Brett L. Hurst, Amit S. Kalgutkar, Emi Kimoto, Lorraine F. Lanyon, Gabrielle H. Lovett, Yajing Lian, Wei Liu, Luis Martinez-Alsina, Stephen Noell, R. Scott Obach, Dafydd R. Owen, Nandini C. Patel, Devendra K. Rai, Matthew R. Reese, Hussin A. Rothan, Sylvie K. Sakata, M. F. Sammons, Jean G. Sathish, Raman Sharma, Claire M. Steppan, Jamison B. Tuttle, Patrick R. Verhoest, Liuqing Wei, Qingyi Yang, Irina Yurgelonis, Yuao Zhu - Journal of Medicinal Chemistry 2024 被引用: 73

  10. Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks

    著者: Suvi T. M. Orr, Sharon L. Ripp, T. Eric Ballard, Jaclyn L. Henderson, Dennis O. Scott, R. Scott Obach, Hao Sun, Amit S. Kalgutkar - Journal of Medicinal Chemistry 2012 被引用: 219

  11. Nonclassical Phenyl Bioisosteres as Effective Replacements in a Series of Novel Open-Source Antimalarials

    著者: Edwin G. Tse, Sevan D. Houston, Craig M. Williams, G. Paul Savage, Louis M. Rendina, Irene Hallyburton, Mark Anderson, Raman Sharma, Gregory S. Walker, R. Scott Obach, Matthew H. Todd - Journal of Medicinal Chemistry 2020 被引用: 149

  12. Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination

    著者: Manthena V. S. Varma, R. Scott Obach, Charles J. Rotter, Howard Miller, George Chang, Stefanus J. Steyn, Ayman El‐Kattan, Matthew D. Troutman - Journal of Medicinal Chemistry 2010 被引用: 325

  13. THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

    著者: Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf, Volker Fischer, Lawrence L. Gan, Scott Grimm, John Y. Kao, Shang‐Ying P. King, Gerald T. Miwa, Lan Ni, Gondi Kumar, James F. McLeod, R. Scott Obach, Stanley Roberts, Amy L. Roe, Anita Shah, Fred Snikeris, John T. Sullivan, Donald Tweedie, José M. Vega, John Walsh, Steven Wrighton - Drug Metabolism and Disposition 2003 被引用: 784

  14. Physicochemical Determinants of Human Renal Clearance

    著者: Manthena V. S. Varma, Bo Feng, R. Scott Obach, Matthew D. Troutman, Jonathan Chupka, Howard Miller, Ayman El‐Kattan - Journal of Medicinal Chemistry 2009 被引用: 209

  15. Prediction of Volume of Distribution Values in Humans for Neutral and Basic Drugs Using Physicochemical Measurements and Plasma Protein Binding Data

    著者: Franco Lombardo, R. Scott Obach, Marina Shalaeva, Feng Gao - Journal of Medicinal Chemistry 2002 被引用: 209

  16. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans

    著者: Heather Eng, Alyssa Dantonio, Eugene P. Kadar, R. Scott Obach, Li Di, Jian Lin, Nandini C. Patel, Britton Boras, Gregory S. Walker, Jonathan J. Novak, Emi Kimoto, Ravi Shankar Prasad Singh, Amit S. Kalgutkar - Drug Metabolism and Disposition 2022 被引用: 116

  17. Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions

    著者: R. Scott Obach, Robert L. Walsky, Karthik Venkatakrishnan - Drug Metabolism and Disposition 2006 被引用: 456

  18. Effective Application of Metabolite Profiling in Drug Design and Discovery

    著者: Matthew A. Cerny, Amit S. Kalgutkar, R. Scott Obach, Raman Sharma, Douglas K. Spracklin, Gregory S. Walker - Journal of Medicinal Chemistry 2020 被引用: 44

  19. A Novel Milli-fluidic Liver Tissue Chip with Continuous Recirculation for Predictive Pharmacokinetics Applications

    著者: Shiny Amala Priya Rajan, Jason Sherfey, Shivam Ohri, Lauren M. Nichols, Jeff Smith, Paarth Parekh, Eugene P. Kadar, Frances Clark, Billy T. George, Lauren Gregory, David A. Tess, J Gosset, Jennifer L. Liras, Emily Geishecker, R. Scott Obach, Murat Cirit - The AAPS Journal 2023 被引用: 32

  20. SERTRALINE IS METABOLIZED BY MULTIPLE CYTOCHROME P450 ENZYMES, MONOAMINE OXIDASES, AND GLUCURONYL TRANSFERASES IN HUMAN: AN IN VITRO STUDY

    著者: R. Scott Obach, Loretta M. Cox, Larry M. Tremaine - Drug Metabolism and Disposition 2004 被引用: 216

  21. Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug

    著者: Md L T Vieira, Brian J. Kirby, Isabelle Ragueneau‐Majlessi, Aleksandra Galetin, Jenny Y. Chien, Heidi J. Einolf, Odette A. Fahmi, Volker Fischer, Adrian J. Fretland, K. Grime, Stephen D. Hall, Richard E. Higgs, David R. Plowchalk, R Riley, Eleanore Seibert, Konstantine W. Skordos, Jan Snoeys, Karthik Venkatakrishnan, Timothy Waterhouse, R. Scott Obach, Eva Gil Berglund, L. Zhang, Ping Zhao, K S Reynolds, S-M Huang - Clinical Pharmacology & Therapeutics 2013 被引用: 101

  22. A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups

    著者: Amit S. Kalgutkar, Iain Gardner, R. Scott Obach, Christopher L. Shaffer, Ernesto Callegari, Kirk R. Henne, Abdul Mutlib, Deepak Dalvie, Jae S. Lee, Yasuhiro Nakai, John P. O’Donnell, Jason Boer, Shawn Harriman - Current Drug Metabolism 2005 被引用: 619

  23. VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES

    著者: Robert L. Walsky, R. Scott Obach - Drug Metabolism and Disposition 2004 被引用: 504

  24. Addressing the Challenges of Low Clearance in Drug Research

    著者: Li Di, R. Scott Obach - The AAPS Journal 2015 被引用: 113